Skip to main content

Aspira Women's Health Inc.

For the period ended Mar 31, 2025. Filed May 19, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 19, 2025

AWHL$0.430.0%Stored close · as of Sep 19, 2025

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31,2025

OR

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______

Commission File Number:001-34810

** **(Exact name of registrant as specified in its charter)

Delaware33-0595156
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
12117 Bee Caves Road, Building III, Suite 100, Austin, Texas78738
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:(512) 519-0400

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareAWHLThe OTC QB Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐Accelerated filer ☐
Non-accelerated filer ☒Smaller reporting company ☒ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No☒

As of May 12, 2025, the registrant had 30,153,924 shares of common stock, par value $0.001 per share, outstanding.

ASPIRA WOMEN’S HEALTH INC.

FORM 10-Q

For the Quarter Ended March 31, 2025

Table of Contents

Page
PART IFinancial Information1
Item 1Financial Statements (unaudited)1
Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 20241
Condensed Consolidated Statements of Operations for the three months ended March 31, 2025 and 20242
Condensed Consolidated Statements of Changes in Stockholders’ Deficit for the three months ended March 31, 2025 and 20243
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2025 and 20245
Notes to Condensed Consolidated Financial Statements6
Item 2Management’s Discussion and Analysis of Financial Condition and Results of Operations21
Item 3Quantitative and Qualitative Disclosures About Market Risk31
Item 4Controls and Procedures31
PART IIOther Information32
Item 1Legal Proceedings32
Item 1ARisk Factors32
Item 2Unregistered Sales of Equity Securities and Use of Proceeds32
Item 3Defaults Upon Senior Securities32
Item 4Mine Safety Disclosures32
Item 5Other Information32
Item 6Exhibits33
SIGNATURES34

The following are registered and unregistered trademarks and service marks of Aspira Women’s Health Inc.: VERMILLIONSM, Aspira Women’s Health®, OVA1®, OVERA®, ASPiRA LABS ®, OvaCalc®, OVASUITESM, ASPiRA GenetiXSM, OVA1PLUS®, OVAWATCH®, EndoCheck SM, ENDOINFORMTM, OVAINFORMTM, OVAInherit SM, Aspira Synergy®, OVA360 SM, ASPIRA IVDSM, and YOUR HEALTH, OUR PASSION®.

i

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.